The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

BackgroundAtopic dermatitis (AD) is a chronically relapsing disease. Few biologics are approved for moderate-to-severe AD, and novel interventions are emerging. We aimed to evaluate the safety and efficacy of lebrikizumab, an IL-13 immunomodulator, as monotherapy vs. placebo in treating moderate-to-...

Full description

Bibliographic Details
Main Authors: Bader Bashrahil, Ziyad Alzahrani, Sahal Samarkandy, Abdullah Aman, Abdulhadi Jfri
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Medicine
Subjects:
atopic dermatitis
eczema
lebrikizumab
anti-IL-13
monoclonal antibodies
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1091271/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1091271/full

Similar Items